HIV-1 infection: New treatment paradigms

European Journal of Clinical Investigation

Volumn 31, Issue 3, 2001, Pages 190-192

  Persidsky, Y ^a,b   Limoges, J ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ANTIVIRAL ACTIVITY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; NOTE; PRIORITY JOURNAL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS;

EID: 0035057377     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2001.00805.x     Document Type: Note

References (28)

1. A regulatory role for astrocytes in HIV-1 encephalitis. An overexpression of eicosanoids, platelet-activating factor, and tumor necrosis factor-alpha by activated HIV-1-infected monocytes is attenuated by primary human astrocytes
2. Platelet-activating factor: A candidate human immunodeficiency virus type-1 infection neurotoxin
3. Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: Relationship to clinical and neurological status
4. Chronic exposure of human neurons to quinolinic acid results in neuronal changes consistent with AIDS dementia complex
5. Immunologic NO synthase: Elevation in severe AIDS dementia and induction by HIV-1 gp41
6. Laureate ESCI award for excellence in clinical science. Cytokines and the human immunodeficiency virus: From bench to bedside. European Society for Clinical Investigation
7. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression
8. Human immunodeficiency virus-specific circulating CD8 T lymphocytes have down-modulated CD3zeta and CD28, key signaling molecules for T-cell activation
9. The Neuropathogenesis of HIV-1-Dementia: A panel discussion
10. Antioxidant therapy for AIDS
11. Thalidomide: Current and potential clinical applications
12. Randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment. Neurological AIDS Research Consortium
13. Suppression of inflammatory neurotoxins by highly active antiretroviral therapy in human immunodeficiency virus-associated dementia
14. Of mice and men: A model of HIV encephalitis
15. Evaluation of antiretroviral drug efficacy for HIV-1 encephalitis in SCID mice
16. Reduction of glial immunity and neuropathology by a PAF antagonist and an MMP and TNF-alpha inhibitor in SCID mice with HIV-1 encephalitis
17. Glutathione and immunophenotypes of T and B lymphocytes in HIV-infected individuals
18. Role of cysteine and glutathione in HIV infection and other diseases associated with muscle wasting and immunological dysfunction
19. Intrace1llular GSH content and HIV replication in human macrophages
20. Improvement of immune functions in HIV infection by sulfur supplementation: Two randomized trials
21. Glutathione deficiency is associated with impaired survival in HIV disease
22. N-acetylcysteine replenishes glutathione in HIV infection
23. Inhibition of murine AIDS by alternate administration of azidothymidine and fludarabine monophosphate
24. New drug combination for treatment of murine AIDS and macrophage protection
25. Opportunistic infections and retrovirus-induced immunodeficiency: Studies of acute and chronic infections with Toxoplasma gondii in mice infected with LP-BM5 murine leukemia viruses
26. Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy
27. Inhibition of RNA transcription: A biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine
28. Modulation of the metabolism of beta-L-(-)-2′,3prime;-dideoxy-3prime;- thiacytidine by thymidine, fludarabine, and nitrobenzylthioinosine